@article{PAR00019680,
  title = {{R}egimens to treat multidrug-resistant tuberculosis : past, present and future perspectives},
  author = {{P}ontali, {E}. and {R}aviglione, {M}. {C}. and {M}igliori, {G}. {B}. and {A}kkerman, {O}. {W}. and {A}lffenaar, {J}. {W}. and {B}lanc, {F}. {X}. and {B}orisov, {S}. and {C}irillo, {D}. {M}. and {D}alcolmo, {M}. and {D}heda, {K}. and {K}ritski, {A}. {L}. and {L}ienhardt, {C}hristian and {O}lliaro, {P}. and {T}adolini, {M}. and {T}iberi, {S}. and {U}dwadia, {Z}. and {G}lobal {T}. {B}. {N}etwork {C}linical {T}rials,},
  editor = {},
  language = {{ENG}},
  abstract = {{O}ver the past few decades, treatment of multidrug-resistant ({MDR})/ extensively drugresistant ({XDR}) tuberculosis ({TB}) has been challenging because of its prolonged duration (up to 2024 months), toxicity, costs and sub-optimal outcomes. {A}fter over 40 years of neglect, two new drugs (bedaquiline and delamanid) have been made available to manage difficult-to-treat {MDR}-/{XDR}-{TB} cases. {W}orld {H}ealth {O}rganization ({WHO}) guidelines published in {M}arch 2019 endorsed the possibility of treating {MDR}-{TB} patients with a full oral regimen, following previous guidelines published in 2016 which launched a shorter regimen lasting 9-10 months. {T}he objectives of this article are to review the main achievements in {MDR}-{TB} treatment through the description of the existing {WHO} strategies, to discuss the main ongoing trials and to shed light on potential future scenarios and revised definitions necessary to manage drug-resistant {TB}.},
  keywords = {},
  booktitle = {},
  journal = {{E}uropean {R}espiratory {R}eview},
  volume = {28},
  numero = {152},
  pages = {art. 190035 [7 p.]},
  ISSN = {0905-9180},
  year = {2019},
  DOI = {10.1183/16000617.0035-2019},
  URL = {https://www.documentation.ird.fr/hor/{PAR}00019680},
}